Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein

<p>Abstract</p> <p>Background</p> <p>The highly conserved nucleoprotein (NP) is an internal protein of influenza virus and is capable of inducing cross-protective immunity against different influenza A viruses, making it a main target of universal influenza vaccine. In...

Full description

Bibliographic Details
Main Authors: Luo Jian, Zheng Dan, Zhang Wenjie, Fang Fang, Wang Hanzhong, Sun Ying, Ding Yahong, Xu Chengfei, Chen Quanjiao, Zhang Hongbo, Huang Ding, Sun Bing, Chen Ze
Format: Article
Language:English
Published: BMC 2012-11-01
Series:Virology Journal
Subjects:
Online Access:http://www.virologyj.com/content/9/1/286
Description
Summary:<p>Abstract</p> <p>Background</p> <p>The highly conserved nucleoprotein (NP) is an internal protein of influenza virus and is capable of inducing cross-protective immunity against different influenza A viruses, making it a main target of universal influenza vaccine. In current study, we characterized the immune response induced by DNA prime-intranasal protein boost strategy based on NP (A/PR/8/34, H1N1) in mouse model, and evaluated its protection ability against a lethal dose challenge of influenza virus.</p> <p>Results</p> <p>The intranasal boost with recombinant NP (rNP) protein could effectively enhance the pre-immune response induced by the NP DNA vaccine in mice. Compared to the vaccination with NP DNA or rNP protein alone, the prime-boost strategy increased the level of NP specific serum antibody, enhanced the T cell immune response, and relatively induced more mucosal IgA antibody. The overall immune response induced by this heterologous prime-boost regimen was Th-1-biased. Furthermore, the immune response in mice induced by this strategy provided not only protection against the homologous virus but also cross-protection against a heterosubtypic H9N2 strain.</p> <p>Conclusions</p> <p>The NP DNA prime-intranasal protein boost strategy may provide an effective strategy for universal influenza vaccine development.</p>
ISSN:1743-422X